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Abstract
Background: Parkinson’s disease is a degenerative neurological condition causing multiple motor and non-motor
symptoms that have a serious adverse effect on quality of life. Management is problematic due to the variable and
fluctuating nature of symptoms, often hourly and daily. The PD_Manager mHealth platform aims to provide a
continuous feed of data on symptoms to improve clinical understanding of the status of any individual patient and
inform care planning. The objectives of this trial are to (1) assess patient (and family carer) perspectives of PD_
Manager regarding comfort, acceptability and ease of use; (2) assess clinician views about the utility of the data
generated by PD_Manager for clinical decision making and the acceptability of the system in clinical practice.
Methods/design: This trial is an unblinded, parallel, two-group, randomised controlled pilot study. A total of 200
persons with Parkinson’s disease (Hoehn and Yahr stage 3, experiencing motor fluctuations at least 2 h per day),
with primary family carers, in three countries (110 Rome, 50 Venice, Italy; 20 each in Ioannina, Greece and Surrey,
England) will be recruited. Following informed consent, baseline information will be gathered, including the
following: age, gender, education, attitudes to technology (patient and carer); time since Parkinson’s diagnosis,
symptom status and comorbidities (patient only). Randomisation will assign participants (1:1 in each country), to
PD_Manager vs control, stratifying by age (1≤ 70 : 1 > 70) and gender (60% M: 40% F). The PD_Manager system
captures continuous data on motor symptoms, sleep, activity, speech quality and emotional state using wearable
devices (wristband, insoles) and a smartphone (with apps) for storing and transmitting the information. Control
group participants will be asked to keep a symptom diary covering the same elements as PD_Manager records.
After a minimum of two weeks, each participant will attend a consultation with a specialist doctor for review of the
data gathered (by either means), and changes to management will be initiated as indicated. Patients, carers and
clinicians will be asked for feedback on the acceptability and utility of the data collection methods. The PD_
Manager intervention, compared to a symptom diary, will be evaluated in a cost-consequences framework.
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Discussion: Information gathered will inform further development of the PD_Manager system and a larger
effectiveness trial.
Trial registration: ISRCTN Registry, ISRCTN17396879. Registered on 15 March 2017.
Keywords: Parkinson’s disease, mHealth, Acceptability, Utility, Cost consequence analysis,
Background
Parkinson’s disease is a degenerative neurological condition
associated with a range of motor and non-motor symptoms
which have a very serious effect on the quality of life of the
people affected. The processes that lead to Parkinson’s, and
to how it manifests in individuals, involve numerous
variables and pathways, and the aetiology is still not fully
understood. Hence, management of the condition is
challenging; people with Parkinson’s differ significantly in
their symptoms and severity, how their disease progresses,
their responses to treatments and their risk of complica-
tions [1]. To optimise treatment, a personalised approach is
therefore needed [2].
A particular characteristic of advanced Parkinson’s
disease is the fluctuation of symptoms and on/off periods.
The mainstay of management is a pharmacological regimen
that becomes increasingly complex as the disease
progresses. Clinicians often find it difficult to identify the
appropriate combination of medications because the
clinical examination is just a snapshot of the patient’s fluc-
tuating state. To accurately titrate the doses, they therefore
have to rely on reports by patients and carers during short
and infrequent clinic appointments. Electronic and paper
motor symptom diaries have been used to improve the
information available to clinicians. Both forms of reporting
have, however, been shown to have similar numbers of
erroneous entries, and a need for detection using automatic
wearable devices has been identified [3]. More continuous
symptom evaluation and feedback to clinicians could
provide the required accurate and reliable information,
with the potential to improve treatment and outcomes.
This is the rationale behind the development of the
PD_Manager system. This mHealth platform aims to
provide a continuous feed of data on symptoms to improve
clinical understanding of the fluctuating status of any indi-
vidual patient and to inform care planning in which differ-
ent experts may be involved, as well as prescribing.
Continuous quantitative monitoring of activities and
medication-induced fluctuations using wearable devices
has been found feasible and useful in prior studies [4, 5],
including exercise interventions [6]. Research has also
focussed on finding the optimal location for monitoring
motor performance [7].
The whole PD_Manager project involves a consortium
of partners from several European countries. The devel-
opment of the PD_Manager platform has been informed
by qualitative research (interviews and focus groups)
which explored the views and attitudes of people with
Parkinson’s, carers and health professionals on the use
of the technology for symptom control. Researchers have
worked with device developers to refine the technology
and undertake proof of concept testing in a hospital set-
ting in Italy and Greece. No adverse events were experi-
enced, and the pilot trial reported in this paper
represents the next step in the testing of the system. The
processes of the PD_Manager system will be checked in
a community setting, and its acceptability and utility in
clinical practice will be explored. Unlike other ongoing
tests of wearable sensors in Parkinson’s patients which
are observational [8], the PD Manager pilot will use a
randomised controlled design. The most common trad-
itional way of gathering information on symptoms from
patients is through patient diaries [9]. This pilot study
will therefore use symptom diaries as a comparator to
the automated and electronic PD_Manager system for
informing patient care and treatment plans.
Research questions
The research questions are the following:
1. What is the utility of PD_Manager as an aid to
clinical decision making (in terms of informing
patient care and treatment plans)?
2. How acceptable is PD_Manager to patients and
carers?
3. What would be the resource implications of the
use of the PD_Manager platform in healthcare
programmes from a provider’s perspective?
Aims and objectives
The aim of the pilot study is to explore the acceptability
and utility of the PD_Manager system to patients, carers
and clinicians, in a community setting, compared to a
symptom diary, to inform further developments and the
design of a larger clinical trial which will assess effective-
ness (patient and carer health outcomes).
The specific objectives of the pilot study are to:
1. Assess patient perspectives of the PD_Manager
mHealth platform regarding comfort, acceptability,
ease of use and understanding of Parkinson’s
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2. Assess the views of clinicians about the
PD_Manager mHealth platform, i.e. usefulness of
the information provided for decision making
regarding patient management; acceptability in
clinical practice; confidence in reliability of the
information
3. Explore the resource implications and costs of the
PD_Manager system for patients/carers and
providers and consider these in the light of
potential outcome differences, compared to the
symptom diary, in a cost-consequences framework.
Methods/design
Design
An unblinded, parallel, two-group randomised con-
trolled pilot study will be conducted to assess the ac-
ceptability and utility of the PD_Manager system,
compared to traditional practices of using a symptom
diary, for the management of people with Parkinson’s
disease. The trial will be undertaken in three countries
(England, Greece and Italy). The protocol and all study
documents were prepared in English and subsequently
translated into Greek and Italian.
Participants
A total of 200 people with Parkinson’s and their carers
(recruited as dyads) will be enrolled into the study
through clinical centres (110 Rome, 50 Venice, Italy; 20
each in Surrey, England and Ioannina, Greece).
The inclusion criteria for people with Parkinson’s are
as follows: (1) diagnosis of idiopathic Parkinson’s disease
according to the UK Brain Bank Criteria; (2) Hoehn and
Yahr disease stage 3 or 4 in OFF state [10]; (3) presence
of motor fluctuations with an average of at least 2 h of
OFF state during the day; (4) availability of a live-in
carer who is willing to take part in the study; (5) good
understanding of local language (in order to be able to
complete the research). The exclusion criteria for people
with Parkinson’s are the following: (1) presence of severe
cognitive impairment (Parkinson’s disease dementia); (2)
comorbidities with stroke or other brain disease; (3)
current involvement in other Parkinson’s research.
For the assessment of the clinical perspective, a mini-
mum of ten neurologists/prescribing clinicians will be
asked to participate (six in Italy, two each in England
and Greece).
Trial processes
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is provided as
Additional file 1. Patient flow through the trial is shown
schematically in Fig 1; the SPIRIT checklist is sum-
marised in Fig 2. Data collection at each stage is shown
in Table 1.
Recruitment, consent and baseline data collection of
patient/carer dyads
People with Parkinson’s and their live-in carers will be
identified by the consultant neurologist at each centre
during routine clinic appointments or following an
inpatient episode and invited to take part in the study. Eli-
gibility will be confirmed by the clinician through comple-
tion of an eligibility checklist (based on the inclusion and
exclusion criteria). The consultant will explain the pur-
pose of the study and provide an information sheet con-
taining full details of the study (see Additional file 2). The
dyads will be given time to consider and asked to contact
the research team if they want further information or wish
to participate. Those who volunteer will be given an ap-
pointment to attend the hospital to meet a research nurse,
where consent will be taken (separately by the person with
Parkinson’s and the carer — see Additional file 2) and
baseline data collected (from records, interview and clin-
ical examination). Participants will be given unique study
identifiers to maintain anonymity.
Baseline data collected (see Table 1) for the person with
Parkinson’s will include disease duration, disease rating —
Unified Parkinson’s Disease Rating Scale (UPDRS) score
[11], disease stage [10], side of onset, current symptoms
(tremor, bradykinesia, rigidity, dyskinesia), more affected
side, Parkinson’s medications, comorbidities and body
mass index (BMI) calculated from ‘height and weight’.
Age, gender, ethnicity, education level and comorbidities
will be collected for both members of the dyad. In
addition they will both be asked if they have a preference
for either the PD_Manager system or the symptom diary
and will be questioned regarding their attitudes and
expectations for each approach (using the Technology
Acceptance Model measure [12, 13] and the Global
Attitude to Technology question [14]), as these attitudes
may affect the views they will express after the trial.
Randomisation
Following baseline data collection, participants will be
randomised to receive either PD_Manager (the interven-
tion) or to be in the control group (symptom diary/no
PD_Manager). Randomisation will be 1:1, blocked and
by quota within each country and will be conducted
using sealed envelopes prepared by an independent stat-
istician. Given the higher incidence for Parkinson’s in
men than in women, its increasing prevalence with age
and a concern that younger people may be more accept-
ing of technology than older people, the objective is to
recruit 40% women and to have one half of each gender
be under 70 years of age.
Participants will be informed of their group allocation
immediately, and a researcher will provide the PD_Ma-
nager devices (intervention group) or the symptom diary
(control group) and give full information about how they
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are to be used over the following 2-week trial period.
Blinding of participants, researchers and clinicians will
not be possible given the nature of the intervention.
Recruitment of clinicians
Volunteers will be sought from amongst clinicians recruit-
ing patients to the study. They will be provided with an in-
formation sheet (see Additional file 2) and asked to provide
informed consent (see Additional file 2). Baseline informa-
tion will be gathered using a short questionnaire covering
qualifications, current role, number of Parkinson’s patients
treated per week and length of time in practice. Partici-
pants will also be asked to complete selected items from
the Technology Acceptance Model measure [12, 13] and
the Global Attitude to Technology question [14].
PD_Manager mHealth intervention
PD_Manager devices comprise a wristband (Microsoft
Band, Microsoft Corporation, Redmond, WA, USA), a
pair of sensor insoles (Moticon GmbH, Munich,
Germany), a smartphone (Aquaris M and U models, BQ,
Madrid, Spain) and a knowledge platform (hosted by
Biotronics 3D, London, UK). The devices are unobtru-
sive. Their wearability, sensitivity and reliability were
tested as part of an earlier proof of concept study, as
was the cleaning and sterilising process that occurs
before devices are transferred between patients [15]. The
intervention will be technically supported by the R&D
partners involved in developing the devices, apps and
knowledge management platform. Researchers will
receive training in use of the devices.
Fig. 1 SPIRIT figure of enrolment, interventions and follow-up assessments
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Data that will be captured include:
– Motor symptoms (tremor, abnormal gait
pattern, freezing of gait, body bradykinesia and
dyskinesia), captured with the sensor insoles,
wristband and phone accelerometers and
gyroscopes, 24/7
– Activity data, including time spent on motor
exercising, from the wristband, 24/7
– Speech quality (sound analysis, phonatory deficit)
captured during scheduled task with the smartphone
microphone (only at the Italian sites)
– Speech analysis (dysarthria, qualitative analysis of
spontaneous speech, mood, intelligibility) through
a web platform (only at the Italian sites)
– Depression, impulsivity and mood, through
questionnaires on smart phone apps (as prompted
by messages)
– Cognitive status through a battery of cognitive
games on tailored apps.
The PD_Manager platform includes an education sec-
tion containing videos and animations on symptoms and
tips and other relevant information regarding personal
care and how to cope with daily life challenges.
The intervention will last 14 days, which is considered
sufficient time to monitor fluctuations for the purpose of
planning treatments. Data from the PD_Manager devices
and apps will be collected. The smartphone automatically
transfers data to the cloud, including the data from the
wristband (which is connected to the smartphone). Data is
stored in the insoles and will be downloaded by the
researcher in encrypted form at the end of the 2-week
follow-up period and immediately transferred to the
cloud. The devices used, body placement and a preview of
motor data collected are shown in Fig. 3.
Fig. 2 PD_Manager schematic diagram of trial process
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Control group
Participants in the control group will be asked to
record motor symptoms and wellbeing over the
2-week trial period. Motor symptoms will be captured
using the Hauser diary, a validated instrument that
allows the patient to record, in a dedicated form, his
or her motor state every 30 min [16]. This diary is
the current gold standard to monitor a patient’s
symptoms at home, and it is also frequently used in
pharmacological clinical trials to assess drug efficacy.
The UCB Parkinson’s Well Being Map™ [17] allows
patients to record and monitor the wide spectrum of
Parkinson’s symptoms, including all those covered by
PD_Manager. It is used to assist preparation for
consultations with the healthcare team. Data from
diaries will be manually entered into the trial
database for analysis.
Concomitant care
All other usual care for participants will continue during
the 2-week trial. The primary care doctors of all people
with Parkinson’s will be informed in writing about their
patient’s participation in the pilot study and the treat-
ment arm to which they have been allocated.
Follow-up
Participants in both groups will receive a phone call from
the research fellow on day 5 and day 10 to check on pro-
gress and answer any questions. They will meet the
clinician at the end of the 2-week trial period for a consult-
ation guided by the data that have been collected. The
follow-up appointment will be arranged during the baseline
meeting, at a time convenient to participants, and will take
place in a clinic at the hospital.
In the intervention group, the clinician reviewing each
patient will receive reports with relevant information and
management suggestions from the PD_Manager software.
In the control group, the content of the patient symptom
diaries will be reviewed. If data from either PD_Manager or
the symptom diary indicate that management changes are
required or referrals to other therapists (such as speech and
language therapist, dietician, occupational therapist, physio-
therapist) would be beneficial, this will be implemented.
Acceptability outcomes
Assessment of acceptability for patients and carers will be
undertaken at the end of the 14-day intervention period
immediately after the feedback consultation with the
clinician. A private room in the clinic will be identi-
fied for this purpose. Views will be collected by inter-
view. Those in the intervention group will be asked
about the following: how comfortable the devices
were and how easy they were to use (determined with
the same wearability and usability questions used in
earlier testing of devices [15]; how useful the feedback
they received from PD_Manager was; their views on
communications with their neurologist regarding the
PD_Manager outputs. The usefulness of the education
Table 1 Summary of data collection at each stage
Participant
group
Data capture at each stage
Baseline During intervention,
PD_Manager group
from devices
During intervention, control
group symptom diaries
Post-intervention,
2 week follow-up
Patient Age, gender, education, disease
duration, disease stage (Hoehn
and Yahr score), main symptoms
(tremor, bradykinesia, rigidity,
dyskinesia), more affected side,
UPDRS scores, current medications,
comorbidities, views on technology
Outcomes: EQ-5D-5L; PDQ-8; NMSS
Motor symptoms (gait,
freezing of gait, bradykinesia,
hypokinesia, dyskinesia,
exercise); non-motor
symptoms (cognition,
sleep, mood)
All symptom domains captured
through the PD_Manager
intervention were self reported
in a motor diary [16] and a
wellbeing map [17] including:
on/off; speech; sleep challenges;
cognitive issues; activities and
physiotherapy
Interviews on acceptability and
ease of use of PD_Manager or
symptom diary; usefulness of the
education section of PD_Manager
Outcomes: EQ-5D-5L; PDQ-8 and
NMSS
Changes in management plan
and referrals
Caregiver Age, gender, education, views
on technology
No information is collected
from caregivers in the
PD_Manager group
No information is collected
from clinicians in the symptom
diary group
Interviews on acceptability and
ease of use of PD_Manager or
symptom diary; usefulness of the
education section of PD_Manager
Outcome: Zarit Caregiver Burden
Scale (using short version)
Outcome: Zarit Caregiver Burden
Scale (using short version)
Clinician Qualifications, current role, number
of Parkinson’s patients/week,
length of time in practice, views
on technology
No information is collected
from clinicians in the
PD_Manager group
No information is collected
from clinicians in the symptom
diary group
Usefulness and value of the
information gathered
(PD_Manager and symptom
diary) for influencing
management decisions; changes
in management, referrals made
EQ-5D-5L EuroQoL-5Dimenions-5Levels, generic health-related quality of life scale [18–20], PDQ-8 Parkinson’s Disease Questionnaire-8, disease specific measure of
health-related quality of life [21, 22], NMSS Non-Motor Symptoms Scale [23], UPDRS Unified Parkinson’s Disease Rating Scale [11]
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section will also be assessed. A separate questionnaire
will be used for participants in the control group to
gather their views about the ease, burden and useful-
ness of the symptom diary. Questionnaires can be ob-
tained from the corresponding author.
Back end data from the PD_Manager system will be
provided to the researchers to enable an analysis of
compliance with use of the devices by members of
the intervention group. These data will be used to in-
dicate how much the patients/carers valued using the
devices.
Face-to-face interviews will be conducted with each
clinician to explore their views about the relative usabil-
ity and acceptability of PD_Manager and the symptom
diary, and the value they perceive they provided in gen-
erating information for clinical decision making. Feed-
back will be sought by means of a semi-structured
interview schedule on perceived usefulness to patients,
carers and professionals, and adaptability to usual work-
ing schedules. The treating clinicians will be asked to
comment on the ease of interpreting the data generated
by the devices and the symptom diary and the ease of
using this data in changing the treatment and care man-
agement of participants, as well as their views on this
means of communicating with participants. The inter-
view schedule can be obtained from the corresponding
author.
Feasibility assessment of effectiveness outcomes
As a test of feasibility, data collection at baseline and
follow-up will include potential outcomes that might be
used in a subsequent fully powered effectiveness trial. Out-
come measures for people with Parkinson’s to be used are:
– EQ-5D-5L (EuroQoL-5Dimensions-5Levels), a
commonly used generic measure of health-related
quality of life across five domains (mobility, usual
activities, self-care, pain, anxiety/depression), each
scored on a 5-point scale (no problem to severe
problem/unable) that provides a utility index for
use in economic evaluations [18–20]
– PDQ-8 (Parkinson’s Disease Questionnaire-8), the
short form of a Parkinson’s disease-specific measure
of health-related quality of life covering eight do-
mains scored on a 5-point scale (never to always/
cannot do at all) [21, 22]
– NMSS (Non-Motor Symptoms Scale) for
Parkinson’s, covering severity and frequency of 30
items across nine domains [23]
Live-in carers will be asked to complete the short ver-
sion of the Zarit Caregiver Burden Scale consisting of 12
items, in two domains: personal strain and role strain.
Each question is scored on a 5-point Likert scale (0,
never to 4, almost always), giving a range of summed
Fig. 3 Devices used, body placement and preview of motor data collected
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scores 0–48, with higher score representing a higher
feeling of being burdened [24].
Analysis
Reporting of results will follow Consolidated Standards of
Reporting Trials (CONSORT) extension guidelines for ran-
domised pilot and feasibility studies [25]. Data relating to
individual participants will be recorded using unique study
identifiers to maintain confidentiality. Research data will be
analysed in each country and merged for comparison pur-
poses. Data relating to quantitative variables (baseline char-
acteristics of participants, acceptability and usability
outcomes at follow-up) will be entered into Statistical Pack-
age for Social Sciences (SPSS) version 24 (IBM SPSS Statis-
tics for Windows, version 24.0, IBM Corporation, Armonk,
NY, USA) and analysed with simple frequencies; the inter-
vention and control groups will be compared using appro-
priate statistical approaches, depending on the nature of
the data. In accordance with the pilot nature of the study,
the analysis will be non-confirmatory. Data from quality of
life and other health outcomes will be inspected for poten-
tial use in any future effectiveness trials. Responses to open
questions relating to participants’ views will be subject to
narrative review. Two independent researchers will read
and re-read comments and agree on themes within the
data. The information generated by the PD_Manager
devices will be analysed by the partners who developed
each device.
We expect most participants to complete the trial,
since the follow-up lasts only 2 weeks and ends with a
consultation with a neurologist, that is in addition to
their usual care. However, it is possible that a participant
will be unable to complete or may wish to withdraw
from the study, in which case their baseline data will be
ignored. Another issue is that participants in the inter-
vention group may not use the technology. We will
know this from the automatic collection of data, and we
will investigate reasons in the follow-up interview. Similarly,
participants in the control group may not complete the
diary, in which case we will similarly explore their reasons.
Sample size calculation
A formal sample size calculation is not normally required
for a pilot study [26–29]. Authors have suggested various
figures ranging from 20 to 70 participants [26, 29–32].
The n = 20 value for number of subjects who will be in-
cluded in England and Greece is at the lower end of this
range, but there will be a total of 200 people with Parkin-
son’s across the three countries, 100 of whom will test the
PD_Manager system. The sample size of 200 for the three
countries was selected based on complexities around the
technologies involved, the desire to compare men and
women and different ages and the desire to capture
possible cross-country setting variations. The findings
from the pilot study will be used to inform the calculation
of a sample size for a future larger scale trial.
Economic evaluation
An economic analysis embedded in the trial will compare
the PD_Manager intervention with the symptom diary with
respect to costs and acceptability and usability outcomes in
a cost-consequences framework [33]. The cost of providing,
maintaining and insuring the PD_Manager devices, access
to the cloud programme and the data infrastructure will be
obtained from the manufacturers and averaged over the ex-
pected number of users. The amount of provider time
spent in training patients and carers, troubleshooting and
in interpreting feedback for both groups will be gathered
through observation and interview and valued using
nationally validated unit costs [34]. The time patients and
carers report spending in using either the PD_Manager
devices or the symptom diaries will be gathered from the
questionnaires administered at follow-up. The various
elements of costs and consequences for patients, carers
and clinicians will be presented in a disaggregated form in
a descriptive table. Reporting will follow Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) [35].
Discussion
When testing of the PD_Manager system is complete
and a final version becomes available for routine use in
clinical practice, it is expected to be used to assess
people with Parkinson’s with symptoms that are hard to
manage and in circumstances where a clinician wants
more information than is provided by patient/carer
self-report to guide medication and management plan-
ning. This pilot study represents a relatively early stage
in the PD_Manager development process, to test accept-
ability and utility of the system from patient, carer and
clinician perspectives. The people with Parkinson’s who
are recruited to the trial may not have symptoms that fit
the description of ‘hard to manage’ and may, in the
opinion of the recruiting doctors, already be optimally
managed. However, their opinions about the acceptabil-
ity and potential usefulness of the PD_Manager system
will still be valuable. All participants will be reimbursed
for all reasonable travel and other out-of-pocket costs
that they incur in order to take part in the research.
The products that constitute the PD_Manager system in
this trial have previously been tested by their respective
manufacturers and shown to be in conformity with rele-
vant directives of the European Commission including
health, safety and environmental protection (i.e. they hold
CE (Conformité Européene/European Conformity) certifi-
cates). The PD_Manager project also tested the devices
for wearability, possible discomfort and safety as part of
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earlier work packages [15]. The participants in these earl-
ier studies were carefully selected to represent the disease
characteristics of the target group. Given the cost and
complexity of the system, devices are reused for multiple
patients, and cleaning instructions provided by the manu-
facturer are scrupulously followed to prevent cross infec-
tion. None of the devices were found to pose any risks or
significant discomfort to the participants [15].
The pilot study has been designed to avoid standard
risks of bias wherever possible. Participants will be rando-
mised to the intervention and control groups to protect
against selection bias, and care has been taken to ensure
both groups receive the same attention at all stages of the
study. Attrition or non-compliance (with devices or symp-
tom diaries) do not constitute an issue but rather are ac-
tions of interest in our analysis of acceptability. However,
the nature of the intervention is such that clinicians can-
not be blinded to the group allocations. Potential does
exist for selective outcome reporting. Hence, we are gath-
ering information on attitudes to technology at baseline
from participants, carers and clinicians.
The pilot study will not evaluate effectiveness and cost
effectiveness of the PD_Manager system, although such a
trial may be warranted if feedback from this pilot is posi-
tive. Outcome measures that may be used in an effective-
ness trial are being tested within the pilot, and the findings
will provide a basis for sample size calculation for a defini-
tive trial. Preliminary cost estimates will also be computed
in the pilot study to provide initial indications about the
value of gathering further evidence from a larger trial.
Data security and confidentiality are major issues in
trials of this sort. Data Protection Directive 95/46/EC,
on the protection of individuals with regard to the pro-
cessing of personal data and on the free movement of
such data, will be strictly followed. Data from devices
will be transferred (as described earlier) and stored in a
web-based cloud database (NoSQL Database -3Dnet) in
anonymised and encrypted format as employed by Apple
for iPhones (a FiWare cloud-based process). The servers
storing the information in the cloud platform are based
on Biotronics 3D’s 3DnetMedical platform in the UK in
an ISO27001-accredited data centre located in London.
They are operated in accordance with the Data Protection
Act. No third parties can access data either from the de-
vices or during transmission. Access to the database will
be strictly controlled and will only be shared with re-
searchers on the PD_Manager project. Administrators of
the web-based cloud database will not have access to data.
The full data management policy of the cloud administra-
tors is available from the corresponding author.
Data collected from participants by researchers will be
recorded by unique study identification number. No
names or personal information will be stored on or with
these forms. Information will be kept in locked filing
cabinets and password-protected computers in restricted
access rooms at the study sites. Data will be shared only
with researchers in the PD_Manager project. All data
gathered will be the property of the PD_Manager con-
sortium, and access by external researchers will only be
authorised by the PD_Manager board. An embargo will
be present until the end of the project with respect to
access for researchers external to the study group.
Results of this pilot study will be presented to the fun-
ders as a report. The research team will write papers for
publication in journals and make conference presenta-
tions to influence the development of future treatment
and services for people with Parkinson’s. A summary of
the study results will be available from the project web-
site (http://www.parkinson-manager.eu/).
Trial status
The protocol version number and date are version 4, 4
May 2017. Recruitment began on 17 October 2017 and
will end on 31 March 2018. Note that recruitment had
not completed when the paper was submitted.
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